Latest Élan Stories
PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,465,462 covering its Once-A-Day LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsule product.
RADNOR, Pa., Dec.
EAST HANOVER, N.J., Nov.
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that a post-hoc analysis showed TYSABRI(R) (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo.
Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial.
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of the first clinical trial of TYSABRI(R) (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial.
TITUSVILLE, N.J., Aug. 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today are presenting detailed results from the companies' 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease at the Alzheimer's Association's International Conference on Alzheimer's Disease 2008 in Chicago, Illinois.
- An armed gangster.